Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia

BMC Infectious Diseases

Volumn 11, Issue , 2011, Pages

  Schweizer, Marin L ^a,b,c   Furuno, Jon P ^a   Harris, Anthony D ^a   Johnson, J Kristie ^a   Shardell, Michelle D ^a   McGregor, Jessina C ^d   Thom, Kerri A ^a   Cosgrove, Sara E ^e   Sakoulas, George ^f,g   Perencevich, Eli N ^a,b,c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF SAN DIEGO   (United States)

^g SHARP MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFAZOLIN; CEFEPIME; CEPHALOSPORIN; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; IMIPENEM; LINEZOLID; NAFCILLIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HAZARD RATIO; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORTALITY; OVERALL SURVIVAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; TREATMENT DURATION; AGED; BACTEREMIA; COMPARATIVE STUDY; DRUG EFFECT; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STATISTICAL MODEL; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; CEFAZOLIN; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; NAFCILLIN; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 80054096461     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-11-279     Document Type: Article

References (30)

1. Institute of Medicine Initial national priorities for comparative effectiveness research. 2009, Washington DC: National Academies Pr, Institute of Medicine.
2. Johnson JK, Khoie T, Shurland S, Kreisel K, Stine OC, Roghmann MC. Skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus USA300 clone. Emerg Infect Dis 2007, 13(8):1195-200. 2828080, 17953091.
3. DeLeo FR, Chambers HF. Reemergence of antibiotic-resistant Staphylococcus aureus in the genomics era. J Clin Invest 2009, 119(9):2464-74. 10.1172/JCI38226, 2735934, 19729844.
4. Barth RH, DeVincenzo N. Use of vancomycin in high-flux hemodialysis: Experience with 130 courses of therapy. Kidney Int 1996, 50(3):929-36. 10.1038/ki.1996.393, 8872968.
5. Centers for Disease Control and Prevention (CDC) Staphylococcus aureus resistant to vancomycin--United States, 2002. MMWR Morb Mortal Wkly Rep 2002, 51(26):565-7. Centers for Disease Control and Prevention (CDC).
6. Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008, 52(4):1330-6. 10.1128/AAC.01602-07, 2292536, 18227177.
7. Chang FY, Peacock JE, Musher DM, Triplett P, MacDonald BB, Mylotte JM, et al. Staphylococcus aureus bacteremia: Recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 2003, 82(5):333-9.
8. Stryjewski ME, Szczech LA, Benjamin DK, Inrig JK, Kanafani ZA, Engemann JJ, et al. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis 2007, 44(2):190-6. 10.1086/510386, 17173215.
9. Kim SH, Kim KH, Kim HB, Kim NJ, Kim EC, Oh MD, et al. Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2008, 52(1):192-7. 10.1128/AAC.00700-07, 2223910, 17984229.
10. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: A meta-analysis. Clin Infect Dis 2003, 36(1):53-9. 10.1086/345476, 12491202.
11. Marra AR, Edmond MB, Forbes BA, Wenzel RP, Bearman GM. Time to blood culture positivity as a predictor of clinical outcome of Staphylococcus aureus bloodstream infection. J Clin Microbiol 2006, 44(4):1342-6. 10.1128/JCM.44.4.1342-1346.2006, 1448655, 16597860.
12. Osih RB, McGregor JC, Rich SE, Moore AC, Furuno JP, Perencevich EN, et al. Impact of empiric antibiotic therapy on outcomes in patients with Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2007, 51(3):839-44. 10.1128/AAC.00901-06, 1803143, 17194829.
13. Furuno JP, Harris AD, Wright MO, Hartley DM, McGregor JC, Gaff HD, et al. Value of performing active surveillance cultures on intensive care unit discharge for detection of methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol 2007, 28(6):666-70. 10.1086/518348, 17520538.
14. Knaus WA, Wagner DP, Draper EA, Zimmerman JE, Bergner M, Bastos PG, et al. The APACHE III prognostic system, risk prediction of hospital mortality for critically ill hospitalized adults. Chest 1991, 100(6):1619-36. 10.1378/chest.100.6.1619, 1959406.
15. Mylotte JM, Aeschlimann JR, Rotella DL. Staphylococcus aureus bacteremia: Factors predicting hospital mortality. Infect Control Hosp Epidemiol 1996, 17(3):165-8. 10.1086/647264, 8708354.
16. Yzerman EP, Boelens HA, Tjhie JH, Kluytmans JA, Mouton JW, Verbrugh HA. Delta APACHE II for predicting course and outcome of nosocomial Staphylococcus aureus bacteremia and its relation to host defense. J Infect Dis 1996, 173(4):914-9. 10.1093/infdis/173.4.914, 8603971.
17. Sunenshine RH, Wright MO, Maragakis LL, Harris AD, Song X, Hebden J, et al. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis 2007, 13(1):97-103. 10.3201/eid1301.060716, 2725827, 17370521.
18. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992, 45(6):613-9. 10.1016/0895-4356(92)90133-8, 1607900.
19. Schweizer ML, Furuno JP, Harris AD, Johnson JK, Shardell MD, McGregor JC, et al. Empiric antibiotic therapy for Staphylococcus aureus bacteremia may not reduce in-hospital mortality: A retrospective cohort study. PLoS One 2010, 5(7):e11432. 10.1371/journal.pone.0011432, 2896397, 20625395.
20. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibiliy testing. CLSI document 2008, M100-S19. Nineteenth Informational Supplement ed., Clinical and Laboratory Standards Institute.
21. Aritaka N, Hanaki H, Cui L, Hiramatsu K. Combination effect of vancomycin and beta-lactams against a Staphylococcus aureus strain, Mu3, with heterogeneous resistance to vancomycin. Antimicrob Agents Chemother 2001, 45(4):1292-4. 10.1128/AAC.45.4.1292-1294.2001, 90459, 11257050.
22. Oshiro T, Nagasawa Z, Hanaki H, Ikeda-Dantsuji Y, Nagayama A. The antagonistic effects of a combination of vancomycin and minocycline in Staphylococcus aureus with heterogeneous resistance to vancomycin. J Infect Chemother 2008, 14(1):15-22. 10.1007/s10156-007-0569-9, 18297444.
23. Joukhadar C, Pillai S, Wennersten C, Moellering RC, Eliopoulos GM. Lack of bactericidal antagonism or synergism in vitro between oxacillin and vancomycin against methicillin-susceptible strains of Staphylococcus aureus. Antimicrob Agents Chemother 2010, 54(2):773-7. 10.1128/AAC.00348-09, 2812142, 19933805.
24. Dhawan VK, Bayer AS, Yeaman MR. Thrombin-induced platelet microbicidal protein susceptibility phenotype influences the outcome of oxacillin prophylaxis and therapy of experimental Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 2000, 44(11):3206-9. 10.1128/AAC.44.11.3206-3209.2000, 101635, 11036055.
25. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011, 52(3):e18-55. 10.1093/cid/ciq146, 21208910.
26. Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 1990, 34(6):1227-31. 171789, 2393284.
27. Lodise TP, McKinnon PS, Levine DP, Rybak MJ. Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother 2007, 51(10):3731-3. 10.1128/AAC.00101-07, 2043293, 17664322.
28. Gentry CA, Rodvold KA, Novak RM, Hershow RC, Naderer OJ. Retrospective evaluation of therapies for Staphylococcus aureus endocarditis. Pharmacotherapy 1997, 17(5):990-7.
29. Gonzalez C, Rubio M, Romero-Vivas J, Gonzalez M, Picazo JJ. Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 1999, 29(5):1171-7. 10.1086/313440, 10524959.
30. Fortun J, Navas E, Martinez-Beltran J, Perez-Molina J, Martin-Davila P, Guerrero A, et al. Short-course therapy for right-side endocarditis due to Staphylococcus aureus in drug abusers: Cloxacillin versus glycopeptides in combination with gentamicin. Clin Infect Dis 2001, 33(1):120-5. 10.1086/320869, 11389505.